Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma

Emeline Tabouret (1, 2) , Françoise Boudouresque (1) , Maryline Barrie (2) , Mona Matta (2) , Celine Boucard (2) , Anderson Loundou (3) , Antoine Carpentier (4) , Marc Sanson (5) , Philippe Metellus (6) , Dominique Figarella-Branger (1, 7) , L'Houcine Ouafik (1, 8) , Olivier Chinot (9, 1)

1 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
2 Neuro-Oncologie [Hôpital de la Timone - APHM]
3 SPMC - Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants
4 Service de neurologie [Hôpital Avicenne]
5 INSERM UMR_S975
6 Service de neurochirurgie
7 ACPNP - Service d'Anatomo-Cyto-Pathologie et de NeuroPathologie [Hôpital de la Timone - APHM]
8 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]
9 TIMONE - Hôpital de la Timone [CHU - APHM]

Domains: Life Sciences [q-bio]; Cancer

Emeline Tabouret, Françoise Boudouresque, Maryline Barrie, Mona Matta, Celine Boucard, et al.. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-Oncology, 2014, 16 (3), pp.392 - 399. ⟨10.1093/neuonc/not226⟩. ⟨hal-01707899⟩